Physician Assistant, Medical · Dallas, TX
NPI
1598908337
Since 2009
Specialty
Physician Assistant, Medical
Code 363AM0700X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
10100 N Central Expy, Ste.100
Dallas, TX, 75231
Phone (214) 373-7374
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$3.6M
124 prescriptions
Company payments, 2025
$40K
From 28 companies
Medicare prescription drug claims, 2024
In 2024, the drug Kimberly R Poarch prescribed most often to Medicare patients was Orladeyo (Berotralstat Hydrochloride), with 22 prescriptions and refills. In total Kimberly R Poarch wrote 124 Medicare prescriptions that cost $3.6M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-08-02.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Orladeyo Berotralstat Hydrochloride | 22 | 22 | Under 11 | $963K |
| Takhzyro Lanadelumab-Flyo | 21 | 21 | Under 11 | $1.0M |
| Dupixent Syringe Dupilumab | 15 | 15 | Under 11 | $54K |
| Haegarda C1 Esterase Inhibitor | 15 | 15 | Under 11 | $766K |
Brand drugs: 101 claims; generic drugs: 23 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kimberly R Poarch $40K ($40K in general payments such as food, travel and fees) from 28 companies. The largest payer was Pharming Healthcare, Inc. with $12K.
| Company | Payments | Amount |
|---|---|---|
| Pharming Healthcare, Inc. | 24 | $12K |
| CSL Behring CSL.AX | 33 | $12K |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 21 | $6,816 |
| BioCryst US Sales Co., LLC | 20 | $4,277 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $2,053 |
| AstraZeneca Pharmaceuticals LP AZN | 24 | $768 |
| Cycle Pharmaceuticals Inc | 6 | $623 |
| Genzyme Corporation SNY | 11 | $264 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $232 |
| GlaxoSmithKline, LLC. GSK | 13 | $225 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.